Simon J. Tulloch, Md

Biography

Dr. Tulloch has more than 25 years of pharmaceutical and biotech experience in clinical development, R&D management, and business roles—both in Europe and the USA. He consults to the industry on strategic R&D issues, clinical development, and medical issues. Dr. Tulloch has been the Chief Medical Officer at InfaCare Inc.—a privately funded biotech company—and spent ten years at Shire Pharmaceuticals. He moved to the USA to establish Shires U.S. research and development organization. Dr. Tulloch built the organization in all areas of drug development, and successfully conducted the development and NDA approval of Adderall XR. During that time, his organization also developed and got NDA approvals for Fosrenol (Shire’s first global NCE) and Equetro, as well as providing CMC, preclinical, and marketing medical support to all of Shire’s U.S. products. Latterly, he assumed the role of head of the global CNS Business Unit. Prior to his time at Shire, Dr. Tulloch spent eight years with Johnson and Johnson companies, including five years as clinical research director for R.W. Johnson PRI’s European R&D facility in Zurich, Switzerland, working on multiple projects in various therapeutic areas and stages of development. He trained in medicine at Oxford University, has a degree in physiology, a diploma in pharmaceutical medicine, and worked for a number of years for the UK National Health Service in hospital posts. 

Research Interest

Clinical Development, R&D management, and Business roles